Integrative bioinformatics analysis identifies METTL1 as a regulator of immune infiltration and prognosis in breast cancer

整合生物信息学分析表明,METTL1是乳腺癌免疫浸润和预后的调节因子。

阅读:2

Abstract

To explore the role of Methyltransferase-like 1 (METTL1) in the prognosis, diagnosis, and immune infiltration of Breast invasive carcinoma (BRCA), transcriptome data of BRCA from The Cancer Genome Atlas (TCGA) database were analyzed. Then, the METTL1 expression in normal and cancer tissues was compared using the DESeq2 package. Next, the diagnostic and prognostic value of METTL1 was evaluated using receiver operating characteristic curves and survival analysis, respectively. Co-expressed genes and differentially expressed genes related to METTL1 were identified using Pearson correlation and Wilcoxon tests, with overlapping genes subjected to protein-protein interaction network construction to identify hub genes via degree algorithm. After that, immune infiltration analyses were performed using CIBERSORT and xCELL algorithms. METTL1 expression was significantly higher in BRCA tissues compared to normal tissues, with significant diagnostic value. Furthermore, BRCA patients with low METTL1 expression showed better 5-year overall survival and disease specific survival than those with high METTL1 expression. A total of 1829 differentially expressed genes and 236 co-expressed genes were identified, with five hub genes selected. These genes, along with METTL1, were positively associated with immunosuppressive cell types, such as regulatory T cells and follicular helper T cells, suggesting their role in shaping an immunosuppressive tumor microenvironment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。